In central Singapore lies a gleaming cluster of complexes – including Nanos, Genome, Helios, Chromos, Proteos, Matrix, and Immunos – whose names hint at the cutting-edge developments taking place within. The 15 complexes form Biopolis, a world-class biomedical research hub where experts from both industry and academia have converged.
Through the construction of this – and other – specialized hubs for various industries, the Singapore government has, over the past few decades, made a concerted effort for its urban plans to go the extra mile for businesses setting up shop.
In general, Singapore has created a conducive environment for industries to set up shop here in two key ways: by locating industrial parks close to key research institutions, and by providing state-of-the-art facilities where businesses can hit the ground running..
Biopolis was constructed at a cost of over S$570 million (US$404 million), and is now home to the laboratories of world-renowned research institutions and multinational corporations (MNCs), including Procter & Gamble (P&G), GlaxoSmithKline, Merck, Chugai and Takeda. Here, an international community of scientists from both the public and private sectors work side-by-side, an arrangement which so far has been a boon for biomedical industry players.